A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Novartis
Eli Lilly and Company
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Curis, Inc.
National Institutes of Health Clinical Center (CC)
Shenzhen BinDeBio Ltd.
Novartis
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Valerio Therapeutics
University of Chicago
National Cancer Institute (NCI)
Pediatric Brain Tumor Consortium